BMCS.US Biotech Medics Ne
- Market cap
- USD 41.1K
- P/E
- -
- P/B
- -
- ROE
- 0.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2025.
Is BMCS.US undervalued?
Graham numberThe Graham number of Biotech Medics Ne cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biotech Medics Ne fundamental analysis
No fundamental analysis for Biotech Medics Ne yet.
Biotech Medics Ne stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biotech Medics Ne
BioTech Medics, Inc. operates as a medical-based holding company. The company offers calcium carbonate reserves for pharmaceutical, cosmetic, dietary supplement, water treatment, paint, pigment, plastics, adhesive, cleaning agents, and sealant applications. It also provides commodity-backed blockchain solutions. BioTech Medics, Inc. was founded in 1997 and is headquartered in Woodland Hills, California.
Full company profileBiotech Medics Ne financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biotech Medics Ne annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Gross Profit | -1.17M | -1.01M | -2.43K | - | - | - | - | - | - | - | - |
| Operating Income | -1.17M | -1.01M | -2.42K | - | -61.4K | -154K | -323K | -115K | -4.69K | -2.92K | -13.4K |
| EBITDA | -3.73K | - | 10.00 | - | 110K | 96.6K | -86.0K | -115K | 186K | -2.92K | -13.4K |
| Net Income | -1.17M | -1.01M | -2.43K | - | -61.4K | -110K | -323K | -115K | -5.62K | -2.92K | -13.4K |
| EPS | -0.01 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 1.01M | 2.43K | - | - | - | 382.00 | 70.0M | 70.0M | 100M | 100M | 100M |
| Total Liabilities | 45.7K | 45.7K | 45.7K | 45.7K | 107K | 187K | 328K | 426K | 432K | 438K | 441K |
| Shareholders' Equity | 968K | -43.3K | -45.7K | -45.7K | -107K | -187K | 69.7M | 69.6M | 99.6M | 99.6M | 99.6M |
| Cash & Short-term Investments | - | - | - | - | - | 9.00 | -726.00 | - | 102.00 | 2.00 | -302.00 |
| Total Debt | - | - | - | - | - | - | - | - | 27.0K | 2.00K | 2.00K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.17M | -1.01M | -2.43K | - | - | -29.6K | -182K | -16.8K | -26.9K | - | 8.00 |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | - | 0.00 | 373.00 | 2.00K | 0.00 | 2.00 | - | 17.00 |
| Free Cash Flow | -1.17M | -1.01M | -2.43K | - | - | -30.0K | -184K | -16.8K | -26.9K | - | -5.00 |
| Ratios | |||||||||||
| ROE | -121.2% | - | - | - | - | - | -0.5% | -0.2% | 0.0% | 0.0% | 0.0% |
| ROA | -115.7% | -41,704.5% | - | - | - | -28,709.4% | -0.5% | -0.2% | 0.0% | 0.0% | 0.0% |
| Debt to Equity | - | - | - | - | - | - | - | - | 0.00x | 0.00x | 0.00x |
What these items mean
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biotech Medics Ne dividends
Biotech Medics Ne has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Nov 16, 2007.
Who owns Biotech Medics Ne
Ownership data of Biotech Medics Ne is not available yet.
Biotech Medics Ne company profile
- Company name
- Biotech Medics Ne
- Ticker
- BMCS.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 5850 CANOGA AVE, Woodland Hills, CA, United States, 91367
- Phone
- 800-988-3782
- Website
- biotecmedics.com
About Biotech Medics Ne
BioTech Medics, Inc. operates as a medical-based holding company. The company offers calcium carbonate reserves for pharmaceutical, cosmetic, dietary supplement, water treatment, paint, pigment, plastics, adhesive, cleaning agents, and sealant applications. It also provides commodity-backed blockchain solutions. BioTech Medics, Inc. was founded in 1997 and is headquartered in Woodland Hills, California.
Biotech Medics Ne management
4- Mr. Keith A. HouserChairman & Interim President · born 1949
- Anthony Keith MillerChief Executive Officer
- Mr. James C. NairneChief Financial Officer
- Mr. Tom WoodSenior Vice President of Sales